Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000389269 | SCV000343424 | uncertain significance | not provided | 2016-06-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000630531 | SCV000751493 | uncertain significance | Duchenne muscular dystrophy | 2021-09-02 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 339 of the DMD protein (p.Val339Ile). The valine residue is moderately conserved and there is a small physicochemical difference between valine and isoleucine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with DMD-related conditions. ClinVar contains an entry for this variant (Variation ID: 289130). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001833388 | SCV002090420 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2020-12-22 | no assertion criteria provided | clinical testing |